

Macro Asia Economics

Why is sterilization so hard?

Part two of our short primer on Asia's policy dilemma

- Foreign exchange market intervention can affect domestic liquidity as cash is injected or withdrawn from an economy
- To maintain control over monetary conditions, central banks across Asia resort to various sterilization operations
- However, such strategy has its limits as it is rarely watertight and frequently proves too costly to maintain for long periods

Hard triangle, again

As we explained elsewhere (see *Something's gotta give*, 11 May 2007), Asia grapples with the consequences of massive balance of payments surpluses. As central banks purchase foreign exchange to prevent their currencies from appreciating too rapidly, they inevitably inject liquidity into the local market. Officials therefore face a textbook dilemma: either they give up effective control over monetary policy, or seek to reduce the build-up in reserves by allowing the currency to appreciate faster or shut down inflows with various types of capital controls. None of these options, of course, are very desirable.

There is, however, another possibility, seemingly allowing central bankers to circumvent the iron law of this impossible trinity: they can use sterilization operations to offset the impact their foreign exchange market interventions have on the money supply. In essence, this requires two steps. First, the authorities purchase dollars in the foreign exchange market, thereby stabilizing the exchange rate but expanding the supply of local currency in the process. As a second step, officials drain the additional liquidity injected into the market using a host of different policy tools. Such sterilization operations, therefore, allow the central bank to maintain control over domestic monetary conditions while at the same time targeting a desired level of the exchange rate.

All of this sounds almost too good to be true; and essentially it is. Sterilization operations have three basic limitations. First, they are never as watertight as one might think, with domestic liquidity inevitably affected over time by foreign exchange market intervention. Second, sterilization operations only postpone the required adjustment, therefore doing little to resolve the underlying dilemma. Third, they are costly. Nevertheless, despite all of these limitations, sterilization operations are widely used, even if their exact extent is not always easy to ascertain. And this matters. If sterilization operations on a massive scale are not sustainable over time, the hard triangle will inevitably reassert itself. Sooner or later, therefore, Asia may have to come to terms with real exchange rate appreciation – via higher inflation or nominal adjustment – or restrict the inflow of capital.


21 May 2007

Frederic Neumann Economist The Hongkong and Shanghai Banking Corporation Limited +852 2822 4556 fredericneumann@hsbc.com.hk

Issuer of The Hongkong and report: Shanghai Banking Corporation Limited

Disclaimer & Disclosures.

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, that form part of it.



As superficial evidence of massive sterilization, consider the following. All else equal, a rise in foreign exchange reserves must lead to a corresponding growth in base money, or M0. We can therefore estimate the rise in M0 if no sterilization had occurred. This is shown by the red bars above, which track the projected FX based growth in M0 over the last year and the last two years, respectively. The grey bars show the actual rise in M0. As is evident, base money grew far less rapidly than the rise in FX reserves would suggest, and, therefore, central banks must have engaged in sterilization. Of course, our measure is far from perfect. For example, reserves can rise autonomously without intervention because of returns on the existing stock of foreign exchange holdings. But still, the graphs make the point quite clear: Asian central bankers had to apply considerable sterilization operations over the last few years to prevent base money from spiralling out of control.

You may get creative

Sterilization operations come in various forms, all of which aim to offset the impact on the domestic money supply of foreign exchange market intervention. To keep matters straightforward, consider the four most common sterilization tools. First, the central bank may sell domestic securities into the open market, thereby withdrawing cash from circulation. Clearly, the central bank needs to possess an adequate amount of such paper to conduct the operation. Moreover, domestic markets have to be liquid enough for such policy to have the desired effect, something which cannot be taken for granted in all Asian markets. In some countries, central banks are also authorized to issue paper directly to manage domestic liquidity. The Bank of Korea, for example, has issued an impressive number of Monetary Stabilization Bonds in recent years, with the amount of outstanding MSBs today about 30% larger than all corporate bonds combined.

Second, authorities may temper money supply growth by raising reserve requirements for the banking system. This, especially, is a potent sterilization tool in many Asian markets still heavily reliant on bank lending. Changing reserve requirements helps to sterilize foreign exchange market intervention via two channels: it directly siphons off cash from circulation as banks park more funds with the central bank, and it raises the effective costs of money in the economy and, therefore, reduces loan demand. Various countries in Asia, most notably China, have in recent times raised reserve requirements to cool money supply growth.


Third, central banks can sterilize their intervention with forward exchange contracts. By lending out their acquired dollars in return for domestic currency, they can drain the cash previously infused into the market to control the spot exchange rate. Once a forward contract comes due, of course, the central bank has to decide whether to accept a rise in base money or roll over the contract. While data is not readily available for all Asian countries, some central banks in the region have seen a rapid rise in forward positions over the past year, which suggests that they play an increasingly important role in sterilization in such countries as Singapore, Thailand, Malaysia, and the Philippines.


Fourth, authorities can use fiscal policy to minimize the effect foreign exchange market intervention has on the money supply. More directly, governments can shift their short-term cash deposits from commercial entities to the central bank. More broadly, the authorities can run counter-cyclical fiscal policies to dampen the money multiplier and, therefore, broad money growth; this, of course, is a heavyhanded tool, but it works nevertheless: by helping to reduce aggregate demand, a fiscal contraction lowers loan growth in an economy. While there is currently little evidence of the use of counter-cyclical fiscal policy for sterilization in Asia, several governments have used their cash balances to help actively manage domestic liquidity. For example, the Philippines recently announced that government social security funds may transfer more of their deposits to the central bank, while the government in Singapore continues to use cash management to help control money supply growth.

Not as easy as it looks

Of course, none of these policies in themselves represent an optimal solution. Moreover, depending on the structure of the economy and the particular macroeconomic environment, a different policy mix may be appropriate for different countries at different times. But apart from finding the optimal set of tools for a particular economy, there are broader problems with sterilization, which render it unsuitable as a long-term solution to the challenges facing Asian central banks, namely the massive build-up in foreign exchange reserves. At a fundamental level, of course, sterilization does not resolve the inherent dilemma of the iron triangle: it may serve to buy some time, but inevitably the authorities will have to address the underlying imbalances.


More concretely, however, there are two operational problems with sterilization that deserve scrutiny because they set a more immediate limit to the ability of central banks to continue to intervene and keep exchange rates from appreciating in light of massive balance of payments surpluses. First is the problem





of leakage. For various practical reasons it remains difficult for authorities to neatly offset the effect of their FX market intervention. For example, while it is relatively easy for the authorities to sterilize the impact on base money by draining cash, their ability to control the money multiplier and, therefore, broad money is more tenuous. Particularly in economies with large balance of payments surpluses, the perceived macroeconomic risks are small, fuelling confidence and a boom in lending that the authorities are ill-equipped to fully contain.

Moreover, tightening monetary conditions aggressively to dampen the money multiplier is, in practice, difficult to do. For one, the authorities find it tricky to raise interest rates as long as high money supply growth has not yet filtered through into more rapid inflation. Given the long-lagged effect of liquidity growth on the price level, even central banks using an inflation targeting regime often are hesitant to tighten pre-emptively. Even more importantly, tightening monetary conditions in an environment of high capital mobility is ultimately self-defeating: high interest rates only serve to attract more inflows, which sets in motion a perpetual cycle of sterilization and tightening. Ultimately, the price, both economic and political, of high interest rates needed to maintain real exchange rate competitiveness may be too great to render sterilization feasible in the long-run.



The second operational limitation of sterilization is cost. Of course, the price tag of different policies can vary considerably. But, apart from fiscal contraction, all sterilization strategies ultimately involve a cost, which needs to be either fiscalized or is borne directly by the private sector. Most commonly, the cost of sterilization is taken to be equal to the negative carry of the central bank: when acquiring foreign exchange and issuing or selling domestic securities in turn, the authorities effectively forego revenue if the returns on their FX holdings are lower than the cost of servicing domestic obligations. Since generally the domestic returns are likely to be higher than dollar returns – a yield differential which serves to attract capital inflows in the first place – most central banks can be safely assumed to suffer from such a negative carry. Interestingly, as the chart shows, in Asia domestic returns are sometimes below, and often not much higher, than dollar interest rates so that central banks in the region have a relative advantage in pursuing sterilization operations.

However, simply looking at yield differentials between, say, domestic 2yr and 10yr yields and their dollar counterparts may understate the true costs of sterilization. Firstly, in illiquid bond markets, yields are a

poor measure for the marginal cost of capital in the economy. Issuance or sale of securities by the authorities, therefore, crowds out the private sector towards more expensive bank borrowing, a process that is evident for example in the Philippines. Of course, this does not represent a direct cost to the central bank, but it does impose a burden on the economy as whole. Second, the illiquid nature of long-term bond markets has meant that central banks needed to issue or sell shorter-term securities. Here, the costs may be lower, and the consequent profits from sterilization greater, but it exposes central banks to balance sheet risks given the maturity mismatch between their foreign exchange assets and domestic obligations. Third, there is an appreciation risk, where over time the value of foreign exchange assets in domestic currency diminishes relative to the value of the authorities' liabilities.

Other sterilization tools similarly involve costs. Take reserve requirements. These fall into two categories: remunerated and unremunerated. In a banking system with a remunerated reserve requirement, the central bank compensates the commercial bank for the holding of reserves, paying a set rate of return. Raising the required reserve threshold in order to sterilize intervention, therefore, represents a direct cost to the authorities. In other banking systems, however, reserves are unremunerated so that the cost of holding higher reserves falls squarely on the banking sector, likely to be passed on in some form via higher borrowing costs to the private sector. Forward contracts also involve a cost, depending on the relative domestic and foreign rates of return, and even shifting government cash deposits to the central bank involves a cost as the state foregoes interest revenue.

In a broader sense, the question remains whether the costs of sterilization represent a hard constraint for the pursuit of sterilization. The central bank, of course, can always stuff the holes in its balance sheet by printing money, unless inflation is a concern. Moreover, officials may have reason to believe that the sterilization costs are outweighed by the benefits of maintaining a competitive exchange rate. Still, the direct costs involved, even if hard to ascertain precisely, render it on balance more difficult to maintain sterilization operations indefinitely. Whether countries in Asia have yet reached breaking point with regard to the costs or the effectiveness of their sterilization operation is difficult to say and beyond the scope of this primer. What is certain, however, is that sterilization is never a lasting solution to the underlying dilemma of massive balance of payments surpluses. For that, it is too hard to maintain.

6. Preferred set of sterilization tools

	Monetary instruments		Fiscal policy	
	Market	Non-market	Fiscal stance	Cash balances
China	PBoC bills, deposit rate adjustments, FX swaps	Reserve ratios	No	
Hong Kong	No sterilisation	No sterilisation	No	Yes
India	Bond issuance, liquidity adjustment facility, repos and reverse repos	Reserve ratios	No	Yes
Indonesia	use of SBIs	Reserve ratios (seldom)	No	
Korea	Monetary Stabilisation Bonds	Reserve ratios	No	
Malaysia	Money market borrowing; CB's own securities, FX swaps	Reserve ratios	No	Yes
Philippines	Repos, reverse repos and outright transactions, FX swaps	Tiering, SDA expansion	No	Yes
Singapore	FX swaps, money mkt intervention, reverse repo		limited	Yes
Thailand	Repos, FX swaps, CB securities	No	No	Yes

Source: BIS, HSBC observations



Disclosure appendix

This report is designed for, and should only be utilised by, institutional investors. Furthermore, HSBC believes an investor's decision to make an investment should depend on individual circumstances such as the investor's existing holdings and other considerations.

Analysts are paid in part by reference to the profitability of HSBC which includes investment banking revenues.

For disclosures in respect of any company, please see the most recently published report on that company available at www.hsbcnet.com/research.

The following analyst(s), who is(are) primarily responsible for this report, certifies(y) that the views expressed herein accurately reflect their personal view(s) about the subject security(ies) and issuer(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Frederic Neumann

* HSBC Legal Entities are listed in the Disclaimer below.

Additional disclosures

- 1 This report is dated as at 21 May 2007.
- 2 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Chinese Wall procedures are in place between the Investment Banking and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.

Macro Asia Economics 21 May 2007

Disclaimer

*in this publication, HSBC Group offices are indicated by the following codes: 'AU' HSBC Bank plc – Sydney Branch and HSBC Bank Australia Limited; 'UK' HSBC Bank plc in London in the United Kingdom; 'DE' HSBC Trinkaus & Burkhardt AG in Dusseldorf, Germany; 'FR' HSBC Securities (France), Paris; 'HK' The Hongkong and Shanghai Banking Corporation Limited, in Hong Kong SAR in China; 'JP' HSBC Securities (Japan) Limited in Tokyo, Japan; 'US' HSBC Securities (USA) Inc., in New York, USA; 'CA' HSBC Bank Canada. (23 November 2005)

Issuer of report

The Hongkong and Shanghai Banking Corporation Limited Level 19, 1 Queen's Road Central Hong Kong SAR Telephone: +852 2843 9111 Telex: 75100 CAPEL HX Fax: +852 2801 4138 Website: www.hsbcnet.com/research

H2RC (X)

The Hongkong and Shanghai Banking Corporation Limited ("HSBC") has issued this research material. The Hongkong and Shanghai Banking Corporation Limited is regulated by the Hong Kong Monetary Authority. This material is distributed in the United Kingdom by HSBC Bank plc, and in Australia by HSBC Bank plc - Sydney Branch (ABN 98 067 329 015) and HSBC Bank Australia Limited (ABN 48 006 434 162) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). It makes no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local laws. This material is distributed in Japan by HSBC Securities (Japan) Limited. This material may be distributed in the United States solely to "major US institutional investors" (as defined in Rule 15a-6 of the US Securities Exchange Act of 1934); such recipients should note that any transactions effected on their behalf will be undertaken through HSBC Securities (USA) Inc. in the United States. Note, however, that HSBC Securities (USA) Inc. is not distributing this report, has not contributed to or participated in its preparation, and does not take responsibility for its contents. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. In the UK this material may only be distributed to institutional and professional customers and is not intended for private customers. It is not to be distributed or passed on, directly or indirectly, to any other person. Any recommendations contained in it are intended for the professional investors to whom it is distributed. This material is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of HSBC only and are subject to change without notice. The decision and responsibility on whether or not to invest must be taken by the reader. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of any companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform banking or underwriting services for or relating to those companies. This material may not be further distributed in whole or in part for any purpose. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. (070905)

© Copyright. The Hongkong and Shanghai Banking Corporation Limited 2007, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of The Hongkong and Shanghai Banking Corporation Limited. MICA (P) 137/08/2006